https://www.change.org/p/the-us-senate-calling-for-a-congressional-investigation-of-the-cdc-idsa-and-aldf/u

Borrelia burgdorferi spirochetal brain infection and Lewy Body Dementia

Carl Tuttle

Hudson, NH, United States

Aug 2, 2022 — 

Latest email to the Federal Tick-Borne Disease Working Group…

———- Original Message ———-
From: CARL TUTTLE <runagain@comcast.net>
To: “tickbornedisease@hhs.gov” <tickbornedisease@hhs.gov>
Cc: (All members of the TBDWG)
Date: 08/02/2022 9:40 AM
Subject: Borrelia burgdorferi spirochetal brain infection and Lewy Body Dementia

To the Tick-Borne Disease Working Group,

Please see the attached publication from Pathologist Alan MacDonald who has discovered borrelia burgdorferi spirochetal brain infection and Lewy Body Dementia.

Microbial DNA globular liquid crystal like deposits inside Lewy bodies in four Lewy dementia patients
https://www.dropbox.com/s/t38vv4vgx5wow5z/MacDonald%20A%20Lewy%20Body%20Dementia%20%26%20Lyme%20Neuroborreliosis%20Medical%20%26%20Clinical%20Rsearch%20Aug%202022.pdf?dl=0

Alan B MacDonald

Abstract

Four autopsy brains demonstrated concurrent evidence of Diffuse Cortical Lewy Body Dementia and active Lyme neuroborreliosis in adjacent brain sites. Lewy bodies In DCLBD contain microbial DNA. Alpha Synuclein proteins, which intrinsically bind to human nuclear DNA also bind to microbial DNA deposits inside Lewy bodies in the cytoplasmic compartment of diseased neurons. This is the first report of an association between spirochetal brain infection and Lewy Body Dementia.

This is just one additional piece of evidence as identified in my Verbal Public Comment that there has been a 30yr deliberate mishandling/avoidance of Lyme disease while refusing to recognize its severity.

Now would be a good time to review how the deception was pulled off using taxpayer dollars through a grant issued by the CDC; an open checkbook handed to Gary Wormser to produce his junk science focusing on the acute stage of disease with bulls-eye rash and early treatment under Grant# RO1 CK 000152

2019 Communication Sent to the TBDWG:

———- Original Message ———-
From: CARL TUTTLE <runagain@comcast.net>
To: gwormser@nymc.edu, tickbornedisease@hhs.gov, brett.giroir@hhs.gov
Cc: mark.dayton@state.mn.us, daniel.tillson@mail.house.gov, kvf1@comcast.net, olx1@cdc.gov, iturko@umd.edu, allen.l.richards.civ@mail.mil, scott.cooper@cms.hhs.gov, ddutko@hanszenlaporte.com, kalachakra108@aol.com, chris.smith@mail.house.gov, adam.durand@mail.house.gov, Anthony.Fauci@nih.hhs.gov, info@smith4nj.com, marisa.kovacs@mail.house.gov, dmartin@tulane.edu, w.robinson@stanford.edu, tamir.elnabarawy@mail.house.gov, matt.hadro@mail.house.gov, collin.peterson@mail.house.gov, smithr@mmc.org, dennis.dixon1@nih.hhs.gov, estella.jones@fda.hhs.gov, monica.herman@mail.house.gov, mary.noonan@mail.house.gov, james.berger@hhs.gov, vanila.singh@hhs.gov, lise.nigrovic@childrens.harvard.edu, sdonta@comcast.net, wendyadams1@gmail.com, ptourad1@jhmi.edu, members@tulane.edu, kbechto1@jhmi.edu, jaucott2@jhmi.edu, cbb0@cdc.gov, RSabatino@LymeSocietyInc.org, NMurawsky@HRMML.com, Schutzer@gmail.com, stillman@cshl.edu, witkowsk@cshl.edu, gtrpaul@aol.com, corey.garry@mail.house.gov, travis.krogman@mail.house.gov, Alex.Azar@HHS.GOV, tickbornedisease@hhs.gov, andrew.dillon@nice.org.uk, nice@nice.org.uk, gillian.leng@nice.org.uk, paul.chrisp@nice.org.uk, Judith.Richardson@nice.org.uk, david.haslam@nice.org.uk, Phil.Fontanarosa@jamanetwork.org, Howard.Bauchner@jamanetwork.org, Rosa.Miranda@jamanetwork.org, Lisa.Hardin@jamanetwork.org, LetEd@jamanetwork.org, Alan_Kadish@nymc.edu, Kathryn_Brady@nymc.edu, Michelle_Cho@nymc.edu, Carol_Scavarda@nymc.edu, Donna_McKenna@nymc.edu
Date: February 9, 2019 at 9:42 AM

Subject: Efficacy of a 14-day course of amoxicillin for patients with erythema migrans

ScienceDirect

Diagnostic Microbiology and Infectious Disease

Efficacy of a 14-day course of amoxicillin for patients with erythema migrans.
https://www.sciencedirect.com/science/article/pii/S0732889318303304

Wormser GP1, Brady KC2, Cho MS2, Scavarda CA2, McKenna D2.

Excerpt:

“….findings provide additional evidence that a 14-day course of 500 mg amoxicillin given 3 times per day is highly effective therapy for patients with early Lyme disease.”

Feb 9, 2019

Division of Infectious Diseases,
New York Medical College,
Valhalla, NY 10595
Attn: Gary P. Wormser, MD

Dr. Wormser,

Once again, as previously stated in the email below; “Your fixation on the acute stage of disease [with bulls-eye rash] after early treatment has done nothing to advance our understanding of how Lyme disease disables its victim.”

Early treatment of strep throat prevents patients from advancing to rheumatic fever which as you know causes irreversible heart damage. If we focused on the acute stage of strep we would never have realized that missed early treatment caused serious life-altering/life-threatening health consequences.

-Ignoring the late stage horribly disabled Lyme population which could total in the millions worldwide.

I noticed that your manuscript did not include the following reference:

July 2017- In Vitro Susceptibility of the Relapsing-Fever Spirochete Borrelia miyamotoi to Antimicrobial Agents.
https://www.ncbi.nlm.nih.gov/pubmed/28674060

Excerpt:

“We were able to show that both B. miyamotoi strains and B. hermsii demonstrated greater susceptibility to doxycycline and azithromycin, equal susceptibility to ceftriaxone and proved to be resistant to amoxicillin in vitro as compared to the B. burgdorferi s.l. isolates.” 

Your retirement Dr. Wormser is highy, highly anticipated.

Carl Tuttle
Lyme Endemic Hudson, NH

NOTE: Wormser’s study was funded directly from the US Centers for Disease Control

Funding: RO1 CK 000152 which appears to be an open checkbook for his junk science.

(Wasteful taxpayer spending)

Cc: Tick Borne Disease Working Group

Assistant Secretary for Health, ADM Brett P. Giroir, M.D.

On January 4, 2019 at 10:48 AM CARL TUTTLE <runagain@comcast.net> wrote:

JAMA

Shapiro ED, Wormser GP. Lyme disease in 2018: what is new (and what is not).
https://jamanetwork.com/journals/jama/article-abstract/2696480

Jan 4, 2019

Division of Infectious Diseases,
New York Medical College,
Valhalla, NY 10595
Attn: Gary P. Wormser, MD

Dr. Wormser,

In reference to your response to my letter to the Editor published in the December 18th issue of JAMA, it would appear that you and your coauthor Dr. Shapiro conveniently ignored my question highlighted below:

Excerpt from my letter to the editor:

Controversies About Lyme Disease
https://jamanetwork.com/journals/jama/article-abstract/2718786

-Carl Tuttle

“It is well known that untreated streptococcal pharyngitis can progress to rheumatic fever, causing irreversible heart damage. Untreated syphilis leads to progressive disability and dementia, and untreated HIV infection progresses to AIDS with significant disability and death. What happens to the patient with Lyme disease who goes months, years or decades before diagnosis because of a false negative serological test?”

Untreated Lyme is destroying lives, ending careers while leaving the patient in financial ruin as reported by the disabled Lyme community for the past three decades. The absence of a bulls-eye rash after tick bite allows patients to progress to severe neurological disease instead of obtaining a prompt diagnosis and early treatment.

I would like to call attention to the following quote taken from an interview with Professor Willy Burgdorfer, the discoverer of the Lyme disease spirochete:

“The controversy in Lyme disease research is a shameful affair. I say that because the whole thing is politically tainted. Money goes to people that have for the past thirty years produced the same thing. Nothing.  – Willy Burgdorfer

Source: (Live interview)

Prof. Willy Burgdorfer Talks About Lyme Disease
https://www.youtube.com/watch?v=dCnrUmAPcOE

Your fixation on the acute stage of disease after early treatment Dr. Wormser has done nothing to advance our understanding of how Lyme disease disables its victim.

For example:

Subjective symptoms after treatment of early Lyme disease.
https://www.ncbi.nlm.nih.gov/pubmed/20102996

Gary Wormser, New York Medical College

(Financed by the U.S. Centers for Disease Control)

RESULTS: 

“At 12 months after enrollment, only 5 (2.2%) of 230 evaluable patients reported new or increased symptoms, and in none of the patients were these symptoms of sufficient severity to be functionally disabling”

_____________________________

Summary of Wormser’s study: Anyone experiencing symptoms after the one-size-fits-all treatment approach is just experiencing nothing more than the “aches and pains of daily living.”

So basically Wormser’s results are then assumed to apply to the entire patient population; in other words, Lyme is no big deal which has wrongly influenced our nation’s response to this serious life-altering health threat. The research into how Lyme disables should have been completed by now but the misclassification of Lyme as a simple nuisance disease (hard to catch and easily treated) has paralyzed the response to this runaway plague.

Many infections as I continue to point out evolve into an entirely different and serious life-altering/life-threatening disease when left untreated.

Post Treatment Lyme Disease Syndrome (PTLDS) after early treatment and untreated Lyme of months, years or decades are two entirely different disease states; the latter being ignored for three decades. Patients who have had a prolonged exposure to the pathogen are almost always incapacitated.

Purposely avoiding the advanced stage of disease hides the horribly disabled and anyone unable to see this is somewhat naive.

So I ask the question Dr. Wormser, What is the motivation for downplaying the severity of Lyme disease while ignoring patient outcry for thirty years?

A prompt response to this inquiry is requested.

Please hit Reply-All as I have carbon copied the Tick Borne Disease Working Group and Assistant Secretary for Health, ADM Brett P. Giroir, M.D.

Carl Tuttle
Lyme Endemic Hudson, NH

_________________

For more:

%d bloggers like this: